Table 2.
Characteristics for patients with cancer in the esophagus, gastroesophageal junction, and stomach who received chemotherapy with curative intention within 6 months from diagnosis (n = 279)
| Cancer site and chemotherapy groups | Cohort | Stage | Mean age (SD) | %Radiotherapy | %Male | ||
|---|---|---|---|---|---|---|---|
| (T1 + T2)/(T3 + T4) | %Npos | %Mpos | |||||
| Esophagus, N | 132 | ||||||
| Cisplatin-fluorouracil | 85 | 14/71 | 81 | 6 | 63.3 (7.5) | 78 | 74 |
| Fluorouracil-oxaliplatin | 23 | 4/19 | 61 | 4 | 67.6 (6.0) | 65 | 78 |
| Carboplatin-fluorouracil | 14 | 3/11 | 64 | 7 | 67.9 (6.7) | 93 | 79 |
| Other chemotherapy | 10 | 3/7 | 50 | 0 | 71.4 (6.4) | 70 | 70 |
| p value | p = 0.01 | p < 0.01 | p = 1.00 | p < 0.01 | p < 0.01 | p = 0.98 | |
| Gastroesophageal junction, N | 59 | ||||||
| Cisplatin-fluorouracil | 34 | 6/28 | 76 | 12 | 60.4 (9.4) | 82 | 91 |
| Fluorouracil-oxaliplatin | 13 | 2/11 | 54 | 0 | 64.5 (9.0) | 54 | 69 |
| Epirubicin-oxaliplatin-capecitabine | 7 | 2/5 | 86 | 14 | 69.1 (4.7) | 14 | 100 |
| Other chemotherapy | 5 | 3/2 | 20 | 0 | 70.2 (11.3) | 40 | 40 |
| p value | p = 0.09 | p = 0.12 | p = 0.75 | p = 0.05 | p < 0.01 | p = 0.03 | |
| Stomach, N | 88 | ||||||
| Epirubicin-oxaliplatin-capecitabine | 71 | 24/47 | 54 | 7 | 58.7 (10.4) | 3 | 61 |
| Fluorouracil-irinotecan | 8 | 0/8 | 88 | 0 | 66.9 (7.2) | 0 | 88 |
| Other chemotherapy | 9 | 4/5 | 56 | 33 | 70.3 (9.0) | 0 | 56 |
| p value | p = 0.17 | p = 0.18 | p = 0.20 | p < 0.01 | p = 0.40 | p = 0.48 | |